Search Within

Robert Motzer

Formats
  1. Journal Article (610)
  2. Meeting Abstract (580)
  3. Book Section (20)
  4. Review (13)
  5. Correspondence (7)
  6. Conference Paper (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (4)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1252)
  2. Genitourinary Oncology Service (1252)
  3. Solid Tumor Oncology Division (1252)
  4. Surgery (292)
  5. Urology (283)
  6. Survivorship Research (254)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (35)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Oxford University Press (112)
  3. Elsevier Science, Inc. (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (87)
  6. American Association for Cancer Research (58)

More Publishers

Results (1252)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma
    Editorial

    Cella, D.; Motzer, R. J.; Suarez, C.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J. F.; Simsek, B.; Zhang, J.; Ivanescu, C.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
    Journal Article

    Grünwald, V.; McKay, R. R.; Buchler, T.; Eto, M.; Park, S. H.; Takagi, T.; Zanetta, S.; Keizman, D.; Suárez, C.; Négrier, S.; more...
    International Journal of Cancer (2025)

    Fulltext@MSK | Save
  • Adjuvant nivolumab for localized renal cell carcinoma at high risk of recurrence after nephrectomy: Part b of the randomized, placebo-controlled, phase III CheckMate 914 Trial
    Journal Article

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H. J.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthélémy, P.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • First and second-line treatments in metastatic renal cell carcinoma
    Review

    Barragan-Carrillo, R.; Saad, E.; Saliby, R. M.; Sun, M.; Albiges, L.; Bex, A.; Heng, D.; Mejean, A.; Motzer, R. J.; Plimack, E. R.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Prospective study of patient, nursing, and oncology provider perspectives on telemedicine visits for renal cell carcinoma clinical trials
    Journal Article

    Doshi, S. D.; Knezevic, A.; Gonzalez, C.; Fischer, P.; Goodman, R.; Gornell, S.; Patel, S.; Puzio, C.; Ritea, A.; Lee, C. H.; more...
    Clinical Genitourinary Cancer (2025)

    Fulltext@MSK | Save
  • Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
    Meeting Abstract

    Venugopal, B.; Choueiri, T. K.; Penkov, K. D.; Albiges, L.; Uemura, H.; Larkin, J.; Tomita, Y.; Wang, J.; Hoffman, J.; Gerhold-Ay, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
    Meeting Abstract

    Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillo, J.; Garmezy, B.; Coelho Barata, P. M.; McKay, R. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • 280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
    Meeting Abstract

    Eto, M.; Motzer, R. J.; Choueiri, T. K.; Haanen, J. B. A. G.; Oya, M.; Uemura, H.; Venugopal, B.; Rini, B. I.; Miyake, H.; Albiges, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • 292P Avelumab + axitinib (A + Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
    Meeting Abstract

    Oya, M.; Motzer, R. J.; Choueiri, T. K.; Haanen, J. B. A. G.; Eto, M.; Uemura, H.; Venugopal, B.; Rini, B. I.; Miyake, H.; Albiges, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Management of kidney cancer relapse to adjuvant pembrolizumab: Early insights and questions for a newly emerging space
    Editorial

    Voss, M. H.; Motzer, R. J.
    European Urology (2024)

    Fulltext@MSK | Save